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OBJECTIVES: Patients with type 2 diabetes are known
to make increased use of health-care resources, but the
impact of specific macro and microvascular complica-
tions on costs is unclear. Here we use regression based
methods to estimate the immediate and long-term impact
of six diabetes-related complications on hospital costs,
using data from the UKPDS, a large (n  5102) and long-
term (median duration 10.3 years) clinical trial.
METHODS: Data on the occurrence and precise timing
of pre-defined diabetes-related complications, and on all
hospitalisations with associated specialties, lengths of
stay, and procedures, were collected routinely for all pa-
tients during the trial. Panel data regression analysis was
used to estimate the immediate impact (i.e. in the year
event occurred) and long-term impact (i.e. in each subse-
quent year) of the following six diabetes-related compli-
cations on hospital costs: fatal and non fatal myocardial
infarction (n  828); fatal and non-fatal stroke (n 
271); heart failure (n  166); angina (n  319); blindness
in one eye (n  166); amputation (n  67). Hospital
costs were calculated using national average specialty-
specific costs per inpatient day, expressed in 1999 £s UK.
RESULTS: All six diabetes-related complications had a
statistically significant impact on hospital costs. In the
year in which the complication occurred, diabetes-related
complications were associated with increased hospital
costs ranging from £995 for loss of sight in one eye to
£5478 for an amputation. In subsequent years the annual
magnitude of this effect ranged from 13% to 33% of the
costs in the initial year.
CONCLUSIONS: Regression analysis on a large and
well-validated, patient-specific data set yields plausible
empirically based estimates of the hospital cost conse-
quences of diabetes-related complications. These will be
of use to other economists and health service researchers,
particularly those interested in assessing the costs of dia-
betes and the cost-effectiveness of interventions within a
modeling framework.
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OBJECTIVES: To compare top down and bottom up
cost estimates of direct health-care costs for diabetes type
2 in the Netherlands.
METHODS: For the top down cost estimates we used
comprehensive Dutch national age and sex-specific cost
of illness estimates for diabetes and diseases related to di-
abetes complications. Costs for diabetes type 2 were sep-
arated by age (age 35 and older) and by prevalence rates
for types 1 and 2. The costs of complications were esti-
mated using costs and prevalence rates for cardiovascular
diseases, neuropathy, nephropathy and retinopathy, com-
bined with relative risks for these complications in pa-
tients with diabetes type 2. The bottom up costs were es-
timated using a sample of 1371 type 2 diabetes patients
for whom their GP reported the total medical consump-
tion related to diabetes and its complications during the
previous six months.
RESULTS: Total medical costs for diabetes type 2 in
1998 were Euro 567 mln according to the bottom up es-
timate versus Euro 519 mln for the top down estimate, or
less than 10 % difference in cost. The costs for in hospital
care, ambulatory care and equipment were very compa-
rable. The cost of medication was higher according to the
bottom up study. The bottom up study identified a larger
amount of cardiovascular and lipid lowering drugs. Both
costing methods show that complications, especially car-
diovascular, are responsible for a substantial portion of
total health-care costs.
CONCLUSIONS: For diabetes type 2 it was demon-
strated that using comprehensive top down disease costs
combined with sound epidemiological data on complica-
tions, can yield valid cost estimates that are quite compa-
rable with bottom up cost estimates.
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OBJECTIVE: To develop a model for predicting hospital
costs in patients with diabetes mellitus.
METHODS: We have previously shown that, in compar-
ison with standard cost models, better prediction can be
achieved with a two-part model that independently pre-
dicts risk of hospitalization and cost of hospitalization. In
this analysis we have developed a three-part model by
adding mortality to the original two-part model, because
patients who die do not necessarily incur hospital costs in
the year of death. Furthermore we have extended the
three-part model to an autoregression model. Age, gen-
der, any hospitalization in the last year, log-hospital costs
in the last year and log-mean costs over all previous years
were included in the model. A Bayesian forecasting
method was used to obtain a predictive distribution of
costs in the next year.
RESULTS: We identified 5672 type 2 diabetic patients in
the Tayside area and analyzed annual hospital costs be-
tween 1988 and 1995. The fitted three-part model showed
that increasing age was associated with increasing mor-
tality and with increasing costs per hospital episode.
However, age was not associated with the risk of hospi-
talization. Cost of hospitalization in previous years was
positively associated with risk of hospitalization (OR 
1.51/ln(mean costs), CI  1.48, 1.53) and mortality (OR 
1.22/ln(mean costs), CI  1.19,1.25). An example of
Bayesian cost forecasting showed that for female patients
aged 50 to 59, increasing hospital costs in the previous
year increased the probability of having a high-cost hos-
